Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2010-023677-19-IT
EUCTR2010-023677-19-IT
Active, not recruiting
Not Applicable

Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010

AZIENDA OSPEDALIERA S. LUIGI GONZAGA0 sitesJune 10, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsBETAFERON*15CONFEZ 0,25MG/ML+EXTAVIA*SC 15FL 250MCG/ML+15SIDIBASE

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 10, 2011
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AZIENDA OSPEDALIERA S. LUIGI GONZAGA

Eligibility Criteria

Inclusion Criteria

  • •\- Patients with RRMS confermed with Mc Donald\`s criterya or with SPMS
  • •\- naive for other previous immunomodular or immunmosoppressive treatment
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Contraindications to treatment with
  • •IFNß and/or vit. D

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Comparison of Interferon-beta-1a and Dexamethasone on hospitalized patients with Covid-19.
IRCT20150622022869N9Yasouj University of Medical Sciences176
Active, not recruiting
Phase 1
Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patientsSARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 daysMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-003872-42-ITIstituto di Farmacologia Traslazionale - CNR60
Recruiting
Phase 3
Comparison of the effect of interferon alfa 2 b (IFN-a2b) drops with mitomycin c during surgery on pterygium recurrence in pterygium surgeryPterygium.Pterygium of eyeH11.0
IRCT20160919029871N5Rasht University of Medical Sciences58
Recruiting
Not Applicable
Role and mechanism of type I interferon in the pathogenesis of anti-MDA5 antibody-positive dermatomyositisAnti-MDA5 antibody-positive dermatomyositis
JPRN-UMIN000049776Chiba University150
Active, not recruiting
Not Applicable
The effect of interferon beta-1a treatment on adaptability of the brain in patients with MSMultiple sclerosisMedDRA version: 14.0Level: PTClassification code 10004504Term: Beta interferon therapySystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2011-003570-89-NLVU University Medical Center